ITEMS IN AFP WITH KEYWORD:

Diabetes

Aug 15, 2017 Issue
Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus [STEPS]

ixisenatide is an easy-to-use, once-daily injectable therapy for the treatment of type 2 diabetes in adults. It is at least as effective as exenatide at reducing A1C and body weight, with similar rates of gastrointestinal adverse effects.


Apr 15, 2017 Issue
Albiglutide (Tanzeum) for Diabetes Mellitus [STEPS]

Reductions in A1C are less with albiglutide than with the first-line therapy metformin, and albiglutide costs significantly more than metformin and sulfonylureas. Albiglutide's ability to reduce diabetes-related morbidity and major cardiovascular events is unknown.


Mar 15, 2017 Issue
Detrimental Effect of Tight Glucose Control on CV Mortality Persists Over Nine Years [POEMs]

The initial Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, which compared standard treatment with intensive control, found that despite good intentions, cardiovascular (CV) and overall mortality are significantly higher when blood glucose levels are lower.


Mar 15, 2017 Issue
Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus [POEMs]

Semaglutide significantly reduced the composite outcome of CV death, nonfatal myocardial infarction, and nonfatal stroke (number needed to treat [NNT] = 43 over 2.1 years). It was generally well tolerated, and it reduced body weight by approximately 6.4 to 9.5 lb (2.9 to 4.3 kg).


Jan 1, 2017 Issue
ADA Updates Standards of Medical Care for Patients with Diabetes Mellitus [Practice Guidelines]

The American Diabetes Association (ADA) recently updated its standards of care to provide the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. Key changes in the 2016 update include new screening recommendations, clarification of diagnostic testing, an...


Dec 15, 2016 Issue
Empagliflozin (Jardiance) for Type 2 Diabetes Mellitus [STEPS]

Empagliflozin can be added to existing type 2 diabetes treatment to lower A1C levels, although there are less expensive options. In older patients with preexisting cardiovascular disease, empagliflozin can decrease all-cause mortality, cardiovascular mortality, and hospitalization for heart failure.


Dec 15, 2016 Issue
Diabetes Mellitus: Management of Gastrointestinal Complications [Article]

Gastrointestinal disorders of diabetes include gastroparesis, nonalcoholic fatty liver disease, gastroesophageal reflux disease, and chronic diarrhea. Find out how to diagnose and treat these conditions.


Nov 15, 2016 Issue
Society for Vascular Surgery Releases Guideline on Managing the Diabetic Foot [Practice Guidelines]

The Society for Vascular Surgery collaborated with the American Podiatric Medical Association and the Society for Vascular Medicine to create evidence-based guidelines to improve the care of patients with a diabetic foot.


Sep 1, 2016 Issue
Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes [POEMs]

In multiple randomized trials, the long-term use of second- or third-generation sulfonylureas in patients with type 2 diabetes is not associated with more deaths, myocardial infarctions (MIs), or strokes. The included trials tended not to report other safety data.


Aug 1, 2016 Issue
Treating Painful Diabetic Peripheral Neuropathy: An Update [Article]

Painful diabetic neuropathic pain causes patients to experience burning pain, paresthesias, and numbness that progress from the feet and hands to the rest of the body. Although several therapeutic modalities are available for its treatment, many patients do not receive adequate care.


Pages: 1 2 3 4 5 6 7 8 9 10 ... 14 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now